NCI-2018-00047, NCT03456843: Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer |
|
|
| Recruiting | 2 | 190 | Japan, US, RoW | Antiandrogen Therapy, ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radical Prostatectomy, Prostatovesiculectomy | Yale University, National Cancer Institute (NCI) | Stage IV Prostate Adenocarcinoma AJCC v7 | 03/27 | 03/27 | | |
NCT05947955: Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Recruiting | 2 | 600 | Europe, US | Rhu-pGSN, recombinant human gelsolin, normal saline, 0.9% sterile saline | BioAegis Therapeutics Inc., Biomedical Advanced Research and Development Authority | Acute Respiratory Distress Syndrome, Infections | 10/26 | 03/27 | | |